Abdolreza Ardeshirylajimi1, Masoud Soleimani2, Saman Hosseinkhani3, Kazem Parivar1, Parichehr Yaghmaei1. 1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran. 2. Department of Hematology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran. 3. Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Abstract
OBJECTIVE: Human induced pluripotent stem cells (iPSCs) have been shown to have promising capacity for stem cell therapy and tissue engineering applications. Therefore, it is essential to compare the ability of these cells with the commonly used mesenchymal stem cells (MSC) for bone tissue engineering in vitro. MATERIALS AND METHODS: In this experimental study, the biological behavior and osteo- genic capacity of the iPSCs were compared with MSCs isolated from human adipose tissue (AT-MSCs) using 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Alizarin red staining, alkaline phosphatase (ALP) activity measurements, calcium content assay and common osteogenic-related genes. Data were reported as the mean ± SD. One-way analysis of variance (ANOVA) was used to compare the results. A p value of less than 0.05 was considered statistically significant. RESULTS: There was a significant difference between the rate of proliferation of the two types of stem cells; iPSCs showed increased proliferation compared to AT-MSCs. During osteogenic differentiation, ALP activity and mineralization were demonstrated to be significantly higher in iPSCs. Although AT-MSCs expressed higher levels of Runx2, iPSCs expressed higher levels of osteonection and osteocalcin during differentiation. CONCLUSION: iPSCs showed a higher capacity for osteogenic differentiation and hold promising potential for bone tissue engineering and cell therapy applications.
OBJECTIVE:Human induced pluripotent stem cells (iPSCs) have been shown to have promising capacity for stem cell therapy and tissue engineering applications. Therefore, it is essential to compare the ability of these cells with the commonly used mesenchymal stem cells (MSC) for bone tissue engineering in vitro. MATERIALS AND METHODS: In this experimental study, the biological behavior and osteo- genic capacity of the iPSCs were compared with MSCs isolated from human adipose tissue (AT-MSCs) using 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Alizarin red staining, alkaline phosphatase (ALP) activity measurements, calcium content assay and common osteogenic-related genes. Data were reported as the mean ± SD. One-way analysis of variance (ANOVA) was used to compare the results. A p value of less than 0.05 was considered statistically significant. RESULTS: There was a significant difference between the rate of proliferation of the two types of stem cells; iPSCs showed increased proliferation compared to AT-MSCs. During osteogenic differentiation, ALP activity and mineralization were demonstrated to be significantly higher in iPSCs. Although AT-MSCs expressed higher levels of Runx2, iPSCs expressed higher levels of osteonection and osteocalcin during differentiation. CONCLUSION: iPSCs showed a higher capacity for osteogenic differentiation and hold promising potential for bone tissue engineering and cell therapy applications.
Since, bone turnover is a long and complicated
process, it is essential to treat bone defects to improve
regeneration and reconstruction (1). Bone
tissue engineering is a new and promising treatment
for bone injuries caused by infections, tumors,
trauma and abnormal skeletal developments
(2-4). Stem cells are noted for their potential for
self-renewal and differentiation into various lineages
with specific functions. In particular, their
potential to give rise to mature and functional osteoblast-
like cells in vitro and in vivo has attracted
many scientists interested in their application as
the live part of bone implants (5-7).Mesenchymal stem cells (MSCs) are a commonly
used source in regenerative medicine and tissue
engineering. They have unusual and useful properties
such as: the potential for intense regeneration,
immunosuppressive features, and a high level of plasticity. There are different sources for deriving
MSCs, like bone marrow and adipose tissue. For
many years, bone marrow derived MSCs (BMMSCs)
were the unique source of autologous stem
cells for tissue engineering, but nowadays it has
been suggested that they be replaced by adipose
tissue derived MSCs (AT-MSCs) (8-10). The main
reason is the increased simplicity of harvesting fat
compared to bone marrow aspiration. In addition,
the yield of stem cells from adipose tissue is higher
than that from bone marrow (11, 12). It has been
shown that the typical MSC yield for bone marrow
is between 1 in 50,000 and 1 in 1 million in
a skeletally mature adult and for adipose tissue is
between 1 in 30 and 1 in 1,000 (11, 12). Other reasons
are the low level of cell morbidity during the
extraction process and the simple equipment and
conditions required for the isolation and growth of
AT-MSCs (13, 14).Recently, Takahashi et al. generated induced
pluripotent stem cells (iPSCs) via the transduction
of murine and human fibroblasts using only
four transcription factors; Oct4, Sox2, c-Myc,
and Klf4 (15, 16). These cells were very similar
to embryonic stem cells (ESCs) in characteristics
such as morphology, gene expression, proliferation,
epigenetic status of pluripotent cellspecific
genes and telomerase activity. Today,
advances in iPSC research have modified the
prospect for tissue engineering and regenerative
medicine. Several studies have reported the
potential application of iPSCs in the treatment
of various diseases (17, 18).Many studies have compared the proliferation
and differentiation characteristics of human ATMSCs
with those of BM-MSCs (19-21), and a
few studies have compared human MSCs with
unrestricted somatic stem cells (USSC) isolated
from umbilical cord blood (22). There have
been many reports on the potential of AT-MSCs
(23) and recently, we ourselves demonstrated
the high proliferation and osteogenic differentiation
potential of human iPSCs (24). However,
as yet, there are no analyses which compare the
osteogenic differentiation potential of human
iPSCs with AT-MSCs. Therefore, in the present
study, AT-MSCs were isolated, characterized
and compared with human iPSCs based on their
biological behavior and their capacity for differentiation
into osteoblastic lineage.
Materials and Methods
Cell culture
Isolation and expansion of adipose tissue derived mesenchymal
stem cells
In this experimental study, for isolation of ATMSCs,
adipose tissue samples were collected
during liposuction operations from five donors
(mean age 40 ± 5, Erfan Hospital, Tehran, Iran)
after informed consent according to guidelines of
the Medical Ethics Committee, Ministry of Health
I. R. Iran. These samples were then were treated
with 0.2% collagenase II under intermittent shaking
at 37˚C for 30 minutes. After centrifugation
(1200 RPM for 15 minutes), the supernatant was
discarded and the cell pellet was treated with RBC
lysis buffer (Dako, Glostrup, Denmark) at room
temperature (RT) for 5 minutes. Samples were
then centrifuged at 1200 RPM for 5 minutes and
the cell pellet was resuspended in a 75 cm2 culture
flask (Nunk) in Dulbecco’s Modified Eagle’s
Medium (DMEM, Invitrogen Co., Carlsbad, CA,
USA) with 10% Fetal Bovine Serum (FBS, Invitrogen
Co., Carlsbad, CA, USA) and incubated
in 95% air and 5% CO2 at 37˚C. After reaching
confluence (about 80-85%) over ten days the cells
were detached using trypsin (2 minutes in 37˚C,
5% CO2) and replated.
Expansion of induced pluripotent stem cells
Human Fibroblast iPSC lines were obtained
from the cell bank (Stem Cells Technology Research
Center (Tehran, Iran) (20). These cells
were expanded according to the protocol reported
in a recent study (24). In brief, the cells
were maintained on feeder layers of SNL76/7
cells treated with mitomycin-C (Invitrogen Co.,
Carlsbad, CA, USA). Human iPSC medium
consisted of DMEM/F12 culture medium supplemented
with 15% knockout serum replacement
(KSR) (Invitrogen Co., Carlsbad, CA,
USA), 0.1 mmol/L nonessential amino acids, 1
mmol/L L-glutamine (all from Invitrogen Co.,
Carlsbad, CA, USA), 0.1 mmol/L b-mercaptoethanol
(Sigma, Munich, Germany), penicillin/
streptomycin (Sigma, Munich, Germany) and 4
ng/mL of human fibroblast growth factor 2 (Invitrogen
Co., Carlsbad, CA, USA), and about
60% of the medium was replaced every day.
Every four to five days human iPSC colonies were detached with 0.1% Collagenase IV, and
replated onto inactivated SNL76/7 for expansion.
MTT assay
AT-MSCs at passage 2 (P2) and human iPSCs
were seeded with an initial cell density of 5000
cells/well in 24-well tissue culture polystyrene
(TCPS) plates and were cultured for five days.
The proliferation of these cells was evaluated
via MTT assay. Thus on each day, 50 μL of
MTT solution (5 mg/mL in DMEM) was added
to each well (n=4), to evaluate the conversion of
MTT to formazan crystals by the mitochondrial
dehydrogenases of the living cells. The plate
was incubated at 37˚C, 5% CO2. After 3.5 hour
incubation the supernatant was removed to examine
the dissolution of the dark-blue intracellular
formazan, and 250 μL dimethyl sulfoxide
(DMSO) as an appropriate solvent was added.
The optical density was read at a wavelength of
570 nm in a micro-plate reader (ELx-800, BIOTEK
instruments, Winooski, VT, USA).For osteo-lineage differentiation, the cells
were cultured in osteogenesis medium containing
basal medium (DMEM + FBS 10%) supplemented
with 10 nM dexamethasone, 0.2
mM ascorbic acid 2-phosphate, and 10 mM
β-glycerophosphate (all from sigma, Munich,
Germany). The medium was changed every 2
days. Finally, at day 21 of culture in inductive
medium the cells were stained with alizarin red
S to assess mineralization.
Flow cytometry
After two weeks of culture, the expression of
surface markers was evaluated using monoclonal
antibodies including Fluorescent isothiocyanate
(FITC)-conjugated mouse anti-humanCD45 (leukocyte common antigen), Phycoerythrin
(PE)-conjugated CD105 (Endoglin or
SH2) CD34, and CD90. The cells were detached
with trypsin/EDTA and incubated with the specific
antibodies or isotype control antibodies
(FITC-or PE-labeled antibodies were included
in each experiment) in 100 μL of 3% bovine serum
albumin in PBS for 1 hour at 4˚C. The cells
were then fixed with 1% paraformaldehyde and
analyzed with a Coulter Epics-XL flow cytometer
(Beckman Coulter, Fullerton, CA, USA)
and Win MDI 2.8 software (Scripps Institute,
La Jolla, CA, USA).
Alkaline phosphatase activity and calcium content assay
ALP activity measurement was performed by
total protein extraction of cells using 200 μL
radio immune precipitation assay (RIPA) lysis
buffer. Then, the lysate was centrifuged at 15000
g at 4˚C for 15 minutes, after the collection of
supernatant, ALP activity was measured using
an ALP assay kit (Parsazmun, Tehran, Iran) according
to the manufacturer’s protocol. Activity
of the enzyme (IU/L) was normalized against
total protein (mg). Mineralization, as a late
marker in the osteogenic differentiation of stem
cells, was also quantified. During osteogenic
differentiation, the amount of calcium minerals
deposited on stem cells was measured using
the cresolphthalein complexone method with a
calcium content assay kit (Parsazmun, Tehran,
Iran). Calcium extraction was performed by 0.6
N HCL (Merck, Darmstadt, Germany). After
the addition of the reagent to calcium solutions,
optical density (OD) was measured at 570 nm.
Calcium content was obtained from the standard
curve of OD versus a serial dilution of calcium
concentrations.
The difference between the mRNA levels of
important bone-related genes in stem cells was
analyzed using real-time RT-PCR. Total RNA was
extracted and random hexamer primed cDNA synthesis
was carried out using Revert Aid first strand
cDNA synthesis kit (Fermentas, Burlington, Canada).
The cDNAs were used for 40 cycle PCR in a
Rotor-gene Q real-time analyzer (Corbett, Sydney,
Australia). Real-time RT-PCR was performed using
Maxima™ SYBR Green/ROX qPCR Master
Mix (Fermentas) followed by melting curve analysis
to confirm PCR specificity. Each reaction was
repeated twice and threshold cycle average was
used for data analysis by Rotor-gene Q software
(Corbett, Sydney, Australia). Genes and related
specific primers are illustrated in table 1. Relative
expression was quantified using ΔΔCt method.
Target genes were normalized against HPRT and
calibrated to iPSCs.Primers used in real-time RT-PCRHPRT1; Hypoxanthine phosphoribosyltransferase 1, Runx2; Runt-related transcription factor 2, Oct4; Octamer-binding transcription
factor 4 and Sox2; SRY (sex determining region Y)-box 2.
Statistical analysis
All experiments were conducted at least for
three times. Data were reported as the mean ±
SD. One-way analysis of variance (ANOVA)
was used to compare the results. A p value of
less than 0.05 was considered statistically significant.
All statistical analyses were conducted
with SPSS software, version 11.0 (SPSS, Chicago,
IL, USA).
Results
Characterization of adipose tissue derived mesenchymal
stem cells
Isolated stem cells from adipose tissue were
characterized based on their surface markers.
AT-MSCs were negative for CD45 and CD34
and were positive for CD90 and CD105 (Fig 1).
iPSCs were also characterized using RT-PCR
for pluripotency genes and teratoma formation
capability (Fig 2). Morphology of human iPSC
colonies seeded on SNL76/7 feeder layers were
similar to human ES morphology (Fig 3A) and
AT-MSCs also showed fibroblast-like and spindle-
shaped morphology when cultured at lowdensity
(Fig 3B). In osteogenic medium (Fig 3C-D), the biomineralization and secreted extracellular
matrix were clearly observed on both
types of stem cell and were visualized by Alizarin
red staining (Fig 3E-F). Calcium depositions
in the two types of stem cell represented a
uniform pattern. However, different amounts of
mineralization were observed in various fields
of AT-MSCs and iPSCs monolayer. The proliferation
rate of stem cells was also significantly
different (Fig 4). According to the results, a
higher rate of proliferation was observed in iPSCs
compared to AT-MSCs.
Fig 1
Flow cytometry analysis of AT-MSCs.
Fig 2
Pluripotency of induced pluripotent stem cells established using the expression of Oct-4, Sox-2 and Nanog(A) and the
explanted teratoma (B).
Fig 3
The morphology of stem cells under basal medium [iPSCs (A) and AT-MSCs (B)]; after 21 days culture in osteogenic
induction medium [iPSCs (C) and AT-MSCs (D)]; and alizarin red staining of stem cells after 21 days culture in osteogenic
induction medium [iPSCs (E) and AT-MSCs (F)], scale bars (100 μm).
Fig 4
Proliferation of induced pluripotent stem cells (iPSCs)
and adipose tissue derived mesenchymal stem cells (AT-MSCs)
on tissue culture polystyrene (TCPS) over a 5 day culture period
(asterisk shows significant difference, p<0.05).
Flow cytometry analysis of AT-MSCs.Pluripotency of induced pluripotent stem cells established using the expression of Oct-4, Sox-2 and Nanog(A) and the
explanted teratoma (B).The morphology of stem cells under basal medium [iPSCs (A) and AT-MSCs (B)]; after 21 days culture in osteogenic
induction medium [iPSCs (C) and AT-MSCs (D)]; and alizarin red staining of stem cells after 21 days culture in osteogenic
induction medium [iPSCs (E) and AT-MSCs (F)], scale bars (100 μm).Proliferation of induced pluripotent stem cells (iPSCs)
and adipose tissue derived mesenchymal stem cells (AT-MSCs)
on tissue culture polystyrene (TCPS) over a 5 day culture period
(asterisk shows significant difference, p<0.05).
Alkaline phosphatase activity and mineralization
of stem cells
ALP activity, as a marker of osteogenesis in
stem cells, was measured during induction of
osteogenesis (Fig 5). ALP activity in all stem
cells showed a similar pattern during osteogenic
differentiation. AT-MSCs showed significantly
higher ALP activity than iPSCs at two time
points (14 and 21 days). Furthermore, higher
ALP activity was measured in iPSCs compared
to AT-MSCs on day 7, however, the difference
was not significant (Fig 6). The calcium content
of both stem cells displayed a similar pattern,
including a peak during osteogenic differentiation.
iPSCs demonstrated a higher level of
calcium deposition than AT-MSCs at all time
points, with a peak on day 14. Furthermore,
significantly higher calcium deposition was
observed in iPSCs compared to AT-MSCs at all
time points.
Fig 5
ALP activity of stem cells during osteogenic differentiation [asterisk shows significant difference between adipose tissue derived
mesenchymal stem cells (AT-MSCs) and induced pluripotent stem cells (iPSCs) on each day, p<0.05].
Fig 6
Calcium content of stem cells during osteogenic differentiation [asterisk shows significant difference between AT-MSsC and
iPSCs on each day at p<0.05].
ALP activity of stem cells during osteogenic differentiation [asterisk shows significant difference between adipose tissue derived
mesenchymal stem cells (AT-MSCs) and induced pluripotent stem cells (iPSCs) on each day, p<0.05].Calcium content of stem cells during osteogenic differentiation [asterisk shows significant difference between AT-MSsC and
iPSCs on each day at p<0.05].
Gene expression analysis
The relative expression of three important
bone-related genes was investigated during osteogenic
differentiation of the two stem cells
(Fig 7). A decreasing trend in the expression of
Runt-related transcription factor 2 (Runx2) was
observed in iPSCs and AT-MSCs during osteogenic
differentiation. This gene was expressed
at a higher level on days 7 and 14 in iPSCs compared
to AT-MSCs. The highest amount of osteonectin
was observed in iPSCs and AT-MSCs
on day 7. In both types of stem cell, osteonectin
expression was down-regulated on days 14 and
21. In both types of stem cell, the expression of
osteocalcin increased similarly during culture.
The expression of osteocalcin during osteogenic
differentiation increased significantly in
iPSCs compared to AT-MSCs.
Fig 7
Relative expression of Osteocalcin, Runx2 and Osteonectin in stem cells on days 7, 14 and 21 during osteogenic differentiation
(asterisk shows significant difference between two groups on each day at p<0.05).
Relative expression of Osteocalcin, Runx2 and Osteonectin in stem cells on days 7, 14 and 21 during osteogenic differentiation
(asterisk shows significant difference between two groups on each day at p<0.05).
Discussion
Currently the use of stem cells to promote bone
healing is being progressed and developed because
of the unique characteristics of these cells, such as
extensive proliferation, differentiation and growth
factor secretion at the site of osseous defects (25-
27). Several studies have shown that CD90 (thymocyte
differentiation antigen 1) and CD105 (known
as endoglin) are surface markers that must be expressed
on the surface of the so-called MSCs (28).
These cells also must lack expression of CD45 and
CD34 which showed their non-hematopoietic origin
(29-31). Flow cytometric data confirmed that
the isolated cells from adipose tissue are mesenchymal.
In the present study, both stem cell types
showed similar patterns of ALP activity during
differentiation into osteoblasts. ALP has a critical
role in osteogenesis due to its role in the cleavage
of calcium phosphate groups and enhancment of
mineralization of the calcium phosphate cements
which are a hallmark of the final osteogenic differentiation
of stem cells in vitro (32-34). Our ALP
activity data showed that iPSCs have superior osteogenic
capacity compared with AT-MSCs at all
time points. In addition, mineralization data confirmed
the patterns of ALP activity in both stem
cells. Matrix mineralization is a result of continuous
mineral deposition due to ALP activity, crystal
nucleation and precipitation during osteogenic
differentiation (35). The significant difference observed
between the level of mineralization in iPSC
compared to AT-MSCs suggests that the movement
of iPSCs toward osteogenic lineage is faster
and higher yield. It seems that this effect could be
a result of the high proliferation rate of iPSCs, as
findings from several studies have demonstrated
that one of the most important items in osteogenic
differentiation is confluency of stem cells (36, 37).
Alizarin red staining showed no significant difference
between the two stem cell types. This result
can be explained by the heterogeneous initial cell
seeding and differential rate of cell attachment.In this study, three important bone-related genes
were selected and their expression was evaluated
for better comparison and understanding of the osteogenic
differentiation behavior of iPSCs and ATMSCs.
Runx2 is an early osteogenic differentiation
gene marker. Up-regulation and significantly
higher levels of Runx2 were observed on days 7
and 14 in AT-MSCs compared to iPSCs. The superior
mineralization of iPSCs can be explained by
up-regulation of the osteonectin gene due to the
important role of osteonectin expression in initial
crystal growth on stem cells during osteogenic
differentiation. This can also explain the higher
expression of osteocalcin in iPSCs compared to
AT-MSCs. Both stem cell types showed a similar
pattern of expression of osteocalcin, but higher expression
of this gene was observed in iPSCs compared
to AT-MSCs. Therefore, high expression of
osteocalcin and down-regulation of Runx2 and osteonectin
as critical osteogenic genes in both types
of stem cell can be a good predictor of their capacity
for differentiation into osteogenic lineage.
In addition, iPSCs showed better results than ATMSCs
in relation to osteogenic gene expression,
which confirmed the higher osteogenic differentiation
potential in iPSCs compared to AT-MSCs.
Conclusion
Taking all the results together, iPSCs showed
a superior capacity for osteogenic differentiation
than AT-MSCs. Although the capacity for osteogenic
differentiation is an important factor when
selecting the cell source for bone cell-based therapies,
the rate of proliferation and senescence-associated
characteristics should also be considered in
the isolation, expansion and selection process.
Authors: James B Mitchell; Kevin McIntosh; Sanjin Zvonic; Sara Garrett; Z Elizabeth Floyd; Amy Kloster; Yuan Di Halvorsen; Robert W Storms; Brian Goh; Gail Kilroy; Xiying Wu; Jeffrey M Gimble Journal: Stem Cells Date: 2005-12-01 Impact factor: 6.277
Authors: I K Moutsatsos; G Turgeman; S Zhou; B G Kurkalli; G Pelled; L Tzur; P Kelley; N Stumm; S Mi; R Müller; Y Zilberman; D Gazit Journal: Mol Ther Date: 2001-04 Impact factor: 11.454
Authors: John K Fraser; Ronda Schreiber; Brian Strem; Min Zhu; Zeni Alfonso; Isabella Wulur; Marc H Hedrick Journal: Nat Clin Pract Cardiovasc Med Date: 2006-03
Authors: Wolfgang Wagner; Frederik Wein; Anja Seckinger; Maria Frankhauser; Ute Wirkner; Ulf Krause; Jonathon Blake; Christian Schwager; Volker Eckstein; Wilhelm Ansorge; Anthony D Ho Journal: Exp Hematol Date: 2005-11 Impact factor: 3.084
Authors: A Ardeshirylajimi; M Mossahebi-Mohammadi; S Vakilian; L Langroudi; E Seyedjafari; A Atashi; M Soleimani Journal: Cell Prolif Date: 2014-12-11 Impact factor: 6.831
Authors: Israa Ahmed Radwan; Dina Rady; Marwa M S Abbass; Sara El Moshy; Nermeen AbuBakr; Christof E Dörfer; Karim M Fawzy El-Sayed Journal: Stem Cells Int Date: 2020-03-29 Impact factor: 5.443